Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Chiu

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Npj Drug Discovery|June 30, 2026
Intranasal monoclonal antibodies do not prevent respiratory infection in a randomized, controlled experimental infection trialJonne Terstappen, Elisabeth E Nibbelke, Stephanie Ascough, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 9, 2022
Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir SizeThomas A Rasmussen, Sunil K Ahuja, Locadiah Kuwanda, et al.
NPJ Vaccines|August 15, 2020
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19Simon P Graham, Rebecca K McLean, Alexandra J Spencer, et al.
Nature Communications|January 23, 2021
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responsesTiong Kit Tan, Pramila Rijal, Rolle Rahikainen, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Npj Drug Discovery|June 30, 2026
Intranasal monoclonal antibodies do not prevent respiratory infection in a randomized, controlled experimental infection trialJonne Terstappen, Elisabeth E Nibbelke, Stephanie Ascough, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 9, 2022
Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir SizeThomas A Rasmussen, Sunil K Ahuja, Locadiah Kuwanda, et al.
NPJ Vaccines|August 15, 2020
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19Simon P Graham, Rebecca K McLean, Alexandra J Spencer, et al.
Nature Communications|January 23, 2021
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responsesTiong Kit Tan, Pramila Rijal, Rolle Rahikainen, et al.
Pageof 2